Boston Scientific Faces Challenge Reclaiming ICD Market Share

Even though Boston Scientific has the FDA’s go-ahead to resume marketing its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators, it will have a tough time recapturing the business it lost during a month-long recall of the devices. A study conducted by Goldman Sachs found that the company’s competitors — mainly Medtronic and St. Jude Medical — are likely to retain 80 percent of the ICD market share Boston Scientific is projected to have lost.
Devices & Diagnostics Letter